AMGN News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AM

Mkt Cap

$212.55B

Volume

2.88M

Next Earnings

November 3rd

Chart Financials Earnings News About Dividends Insider Filings

The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.The Motley Fool · Sep 22, 2026

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial OpportunitiesA comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.GlobeNewswire Inc. · Sep 22, 2026

Should You Invest $1,000 in SCHD Right Now?The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22.8% year-to-date in 2026, outperforming the S&P 500's 11.8% gain. The rotation toward value and dividend stocks is expected to continue due to inflation concerns, higher interest rates, strong corporate earnings growth, and shrinking valuations. The ETF's focus on high-quality dividend-paying stocks positions it well for further gains.The Motley Fool · Sep 22, 2026

Veeva Expands Amgen Partnership With Global Vault CRM Rollout PlanVeeva Systems announced that Amgen has selected its Vault CRM platform for global deployment, extending their partnership of over a decade. The deal reinforces Veeva's commercial business momentum, with the company reporting its best CRM quarter ever, 180+ live Vault CRM customers, and confidence in maintaining over 70% market share in life sciences CRM. The global healthcare CRM market is projected to grow at a 6.2% CAGR from 2026 to 2033.Zacks Investment Research · Sep 21, 2026

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsightThe psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.GlobeNewswire Inc. · Sep 21, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateBiotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.Zacks Investment Research · Sep 21, 2026

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.Zacks Investment Research · Sep 18, 2026

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeThe global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Sep 17, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).Zacks Investment Research · Sep 16, 2026

4 Defensive Stocks to Take Refuge in as Consumer Sentiment PlummetsWith consumer sentiment hitting a 9-year low amid surging inflation and geopolitical tensions, investors are advised to consider defensive stocks from consumer staples and healthcare sectors. Four recommended stocks are Archer-Daniels-Midland (ADM), The Vita Coco Company (COCO), Amgen (AMGN), and Centene Corporation (CNC), all showing strong earnings growth and improved analyst estimates.Zacks Investment Research · Sep 15, 2026

AM

AMGNAmgen Inc

AMGN

Pay with—

Available Balance0.00

Your PositionYou don't own any AMGN yet.

Related Tickers

Earnings

Dividends

Last · Aug 21Quarterly

Amount$2.52

Yield2.42%

Annual$9.94